Track Record

Powering Successes Since 2002

With a portfolio of 350+ companies across the health IT, medical device and bio-pharmaceutical sectors, BioEnterprise has generated XXX in investment and XXX in returns since XXXX.

With an entirely healthcare-focused team of executives-in-residence and other advisors, BioEnterprise helps startups uncover new sources of growth capital, access top talent, create effective business strategy and forge new partnerships. Through a shared vision with partner institutions, including Cleveland Clinic, University Hospitals, Case Western Reserve University and The MetroHealth System, BioEnterprise is expanding the region’s bioscience industry, creating regional jobs and making Cleveland a national leader in healthcare innovation.

Our Companies
Apply to Join
bioengineering2

$5.6B

Estimated value of the Northeast Ohio bioscience community

$22B

Northeast Ohio's healthcare GDP; up 37% since 2001

700+

Biotech, HIT, and medical device businesses in NEO

75

Bioscience exits in Northeast Ohio since 2002, totalling $11B, not including deals with undisclosed terms

XXX

Active investors in Northeast Ohio bioscience companies

SUCCESS STORIES

Athersys

First tenant of the BioEnterprise Incubator in 2002, where it developed a pharmaceutical stem cell therapy called MultiStem to treat diseases and conditions in the neurological, inflammatory and immune, and cardiovascular areas. Now a $255M company that went public in 2007.

Convelo Therapeutics

Developer of regenerative medicines to treat multiple sclerosis. Raised $13M in growth capital since 2017 with on-loan BioEnterprise employees to fuel growth. In 2019, entered strategic partnership with Genentech with an option to acquire.

BioMotiv

Drug development acceleration partner to UH Harrington Discovery Institute within Harrington Project for Discovery and Development. Launched at BioEnterprise Incubator, with $145M in growth capital raised to date and a recently announced partnership with pharmaceutical giant Bristol-Myers Squibb.

CardioInsight

Invented a non-invasive mapping technology for electrical disorders of the heart in 2004, commercialized by CWRU researchers. Raised $37M in growth capital before being acquired by Medtronic in 2015.

Explore Portfolio
Apply to Join